Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study

CardioRenal Medicine

Volumn 5, Issue 4, 2015, Pages 246-253

  Ben Assa, Eyal ^a   Shacham, Yacov ^a   Shashar, Moshe ^a   Leshem Rubinow, Eran ^a   Gal Oz, Amir ^a   Schwartz, Idit F ^a   Schwartz, Doron ^a   Silverberg, Donald S ^a   Chernin, Gil ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anemia; Cardiorenal syndrome; Chronic kidney disease; Erythropoiesis stimulating agents; Heart failure; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

AGED; ANEMIA; ARTICLE; CARDIORENAL SYNDROME; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84945919904     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000433564     Document Type: Article

References (26)

1. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al: Anemia and mortality in heart failure patients: A systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-827.
2. Silverberg DS, Wexler D, Palazzuoli A, Iaina A, Schwartz D: The anemia of heart failure. Acta Haematol 2009; 122: 109-119.
3. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K: Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 2013; 9: 99-111.
4. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM: Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003; 14: 2919-2925.
5. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, et al: Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40: 27-33.
6. Silverberg DS: The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev 2011; 16: 609-614.
7. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
8. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al: Beneficial effects of longterm intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657-668.
9. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al: Meta-analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
10. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
11. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al: Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
12. Besarab A, Horl WH, Silverberg D: Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 2009; 14(suppl 1):22-33.
13. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, et al: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736.
14. Henry DH, Dahl NV, Auerbach MA: Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87: 308-310.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
16. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P: Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816-829.
17. Terrovitis JV, Kaldara E, Ntalianis A, Sventzouri S, Kapelios C, Barbarousi D, et al: Intravenous iron alone is equally effective with the combination of iron and erythropoietin for the treatment of iron-deficiency anemia in advanced heart failure. J Am Coll Cardiol 2012; 60: 2255-2256.
18. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, et al: The effect of IV iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212-219.
19. Sunder-Plassmann G, Spitzauer S, Horl WH: The dilemma of evaluating iron status in dialysis patients-limitations of available diagnostic procedures. Nephrol Dial Transplant 1997; 12: 1575-1580.
20. Del Vecchio L, Locatelli F: Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf 2012; 11: 923-931.
21. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al: Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219.
22. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D: Treatment of anemia in patients with heart disease: A systematic review. Ann Intern Med 2013; 159: 746-757.
23. Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P: Treatment of anemia in patients with heart disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013; 159: 770-779.
24. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
25. Van Buren P, Velez RL, Vaziri ND, Zhou XJ: Iron overdose: A contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012; 44: 499-507.
26. Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000.